Douglas Davis, MD
Neurology · Salina, KSNPI 1386056083
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,950 of the $100,284 with a category attached, or 82.7%. AbbVie accounts for 86.0% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2022 at $33,328 and has fallen 79.3% since, to $6,914 in 2025. Among neurology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 764 payments — averaging $131.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$86K
- Pfizer$4K
- E.r. Squibb & Sons, L.L.C.$3K
- Bristol Myers Squibb$2K
- Eisai Inc.$437
- Genentech USA, Inc.$351
- plus $4K from 35 others
What the payments were for
- Consulting fees$2,7583%
- Speaking & faculty fees$82,95083%
- Travel & lodging$4,2714%
- Food & beverage$10,09110%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$45,268
- UBRELVY$29,756
- QULIPTA$13,792
- NURTEC ODT$3,150
- TYSABRI$150
How this compares
$100,284 in reported general payments places this provider in the 90th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 19 | $94,178 |
| NourianzIstradefylline | 19 | $35,077 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $31,549 |
| Nurtec OdtRimegepant Sulfate | 18 | $27,335 |
| QuliptaAtogepant | 23 | $26,297 |
| GlatopaGlatiramer Acetate | 12 | $23,980 |
| UbrelvyUbrogepant | 18 | $19,669 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 297 | $10,304 |
| Emgality PenGalcanezumab-Gnlm | 11 | $8,353 |
| Rivastigmine | 29 | $7,480 |
| Depakote ErDivalproex Sodium | 12 | $7,430 |
| Lacosamide | 24 | $5,430 |
| Memantine Hcl | 170 | $5,205 |
| AmantadineAmantadine Hcl | 86 | $3,437 |
| Levetiracetam | 168 | $3,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $330 | $94,17819 claims |
| AbbVieQulipta, Ubrelvy | $86,249 | $45,96741 claims |
| Kyowa Kirin, Inc.Nourianz | $340 | $35,07719 claims |
| PfizerNurtec Odt | $4,100 | $27,33518 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $52 | $3,43244 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 131 neurology providers in Kansas.
Other neurology in Salina
- Trent DavisSalina$1K
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Sheetal MalikTopeka$137K
- Richard DubinskyKansas City$122K
- Barbara Jean OttleyHays$116K
- Jeffrey BurnsKansas City$115K
- Amanda ThuringerKansas City$87K
- Mamatha PasnoorKansas City$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.